SCHEMBL6775862

SCHEMBL6775862

COc1cccc(-n2nc(C(C)C)c3c2CC(C)CC3=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.39
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
CSNK2A3 Q8NEV1 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.38
MAPT P10636 4/20 0.38
RAB9A P51151 3/20 0.38
KMT2A Q03164 3/20 0.38
NPC1 O15118 2/20 0.38
HTT P42858 2/20 0.38
MEN1 O00255 2/20 0.38
HSD17B10 Q99714 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
POLB P06746 1/20 0.37
SRC P12931 1/20 0.37
MGLL Q99685 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777339 0.88 CASP1 (0.39) SMN1; SMN2MAPTRAB9AKMT2ANPC1
SCHEMBL6770441 0.86 SRC (0.41) ABCG2CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL6772063 0.86 OPRM1 (0.48) SMN1; SMN2MAPTRAB9AKMT2ANPC1
SCHEMBL6164455 0.85 ABCG2 (0.47) ABCG2CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL6772323 0.83 GPBAR1 (0.41) SMN1; SMN2MAPTRAB9AKMT2ANPC1
SCHEMBL6766708 0.82 RIPK2 (0.48) SMN1; SMN2MAPTRAB9AKMT2ANPC1
SCHEMBL6771294 0.82 SRC (0.49) ABCG2CSNK2A2CSNK2BCSNK2A1SMN1; SMN2
SCHEMBL6766537 0.81 ALDH1A1 (0.41) ABCG2SMN1; SMN2MAPTRAB9AKMT2A
SCHEMBL6777174 0.80 OPRM1 (0.58) SRC
SCHEMBL6772144 0.79 RIPK2 (0.36) ABCG2CSNK2A2CSNK2BCSNK2A1CSNK2A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716856-B1 CELL PROLIFERATIVE DISORDERS OR ALZHEIMER'S DISEASE; REDUCED TOXICITY; CDK/CYCLIN KINASE INHIBITORY ACTIVITY PHARMACIA & TUBJOHN SPA (IT) 2004-04-06 US disclosed